Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Rachel Tanos(Children's Healthcare of Atlanta), Kelly C. Goldsmith(Emory University)
Cited by 38
Related Papers
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
|Nature Medicine|2023|125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
|Clinical Cancer Research|2018|88
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma
|Cell Reports Medicine|2023|16